Monday, October 22, 2012

Astellas launches Gonax (Degarelix Acetate) for Prostate Cancer in Japan

In January 2006, Astellas and Ferring Pharmaceuticals entered into a license agreement that gives Astellas exclusive rights to develop and market degarelix for the treatment of prostate cancer in Japan.

Gonax was granted Japanese marketing approval on June 29, 2012 and listed on the NHI price listing on August 28, 2012. The approval was based on In Phase II studies in Japan and the abroad Phase III studies,. In the clinical trials, Gonax suppressed and maintained the blood testosterone below castration from Day 3 and during the whole treatment period, without a testosterone surge which frequently occurs with GnRH agonist treatment. Also, based on the safety results, Gonax appears to be safe and well tolerated